Related Experiment Videos
Potential and novel therapies for asthma
1University Medicine, Southampton General Hospital Southampton, SO 16 6YD, UK.
The Journal of the Association of Physicians of India
|April 20, 2001
Summary
New asthma therapies target inflammation by interrupting key mediators like leukotrienes and cytokines. These novel treatments, including monoclonal antibodies and targeted immunomodulators, show promise for future asthma management.
Area of Science:
- Pulmonology
- Immunology
- Pharmacology
Background:
- Asthma is a chronic inflammatory airway disease characterized by airflow obstruction.
- Key cellular players include mast cells, eosinophils, neutrophils, and T helper 2 (TH2) lymphocytes.
- These cells release mediators and cytokines driving asthma's pathophysiology.
Purpose of the Study:
- To review novel and potential pharmacological therapies for asthma management.
- To discuss agents targeting specific inflammatory pathways and mediators.
- To explore future directions in targeted asthma treatment.
Main Methods:
- Review of pharmacological agents targeting asthma pathophysiology.
- Discussion of therapies interrupting leukotriene synthesis and action.
- Analysis of cytokine antagonism, monoclonal antibodies, PDE inhibitors, and immunomodulators.
Main Results:
- Identified various novel therapeutic strategies for asthma.
- Highlighted agents that modulate inflammatory pathways.
- Acknowledged that most therapies are in early developmental stages.
Conclusions:
- Improved understanding of asthma mechanisms fuels novel therapeutic development.
- Targeted therapies offer potential for future asthma management.
- Emerging treatments may significantly impact the clinical landscape of asthma care.